知镜 Cognispect · 医学文献与研究工作台

Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection.

Cheng N, Ouellette TW, Skead K, Singhawansa A, Elliott M, Cescon DW, Bratman SV, De Carvalho DD, Soave D, Awadalla P.
Cell genomics · 2026-09-21 · PMID 42767223

文献摘要

Genome-wide cell-free DNA (cfDNA) methylation profiling of 491 pre-diagnosis breast and prostate cancer plasma samples, some collected up to nine years before diagnosis, identifies early cancer-associated epigenetic alterations and predictive signatures. Differentially methylated regions were enriched in regulatory and repetitive elements and reflected cancer-tissue- and immune-cell-associated DNA methylation patterns. Logistic regression models trained on discovery set samples showed that cfDNA silencer-region methylation robustly predicted future prostate cancer, with high-risk individuals exhibiting a 3.55-fold increased hazard of developing prostate cancer. Enhancer hypermethylation modestly predicted incident breast cancer but strongly distinguished established late-stage breast cancers, with high-risk individuals showing a 2.3-fold increased hazard. These results highlight cfDNA methylation as a promising biomarker for early cancer risk prediction and surveillance.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。